Overview
PT-141 is a research-grade peptide compound that has attracted significant attention in the scientific community for its role in bioactive optimization. Bremelanotide — MC3R/MC4R agonist for melanocortin receptor research pathways.
This compound belongs to the bioactive category of research peptides and has been the subject of numerous preclinical investigations. Its unique molecular properties make it a valuable tool for researchers exploring novel therapeutic pathways.
PT-141 activates melanocortin MC3R and MC4R receptors in the CNS, modulating dopamine activity and neural pathways via MC3R/MC4R pathway activation independent of vascular mechanisms. The growing body of published literature continues to expand our understanding of this compound's potential applications in laboratory settings.
Mechanism of Action
PT-141 activates melanocortin MC3R and MC4R receptors in the CNS, modulating dopamine activity and neural pathways via MC3R/MC4R pathway activation independent of vascular mechanisms.
The signaling pathways activated by PT-141 continue to be mapped through proteomic and transcriptomic analyses. Current research focuses on identifying the specific receptor subtypes and downstream effectors responsible for the observed biological responses. Understanding these molecular interactions is critical for advancing the compound from preclinical investigation toward potential translational applications.
Research Areas
- Growth hormone secretion pathway analysis
- Neurotrophic factor expression research
- Receptor binding kinetics
- Hormonal axis modulation
- Signal transduction research
Compound Specifications
| CAS Number | 189691-06-3 |
| Purity | ≥99% HPLC-MS verified |
| Storage | −20 °C. Light-sensitive. |
| Category | Bioactive |
| Price | €49 |
| Format | 10mg lyophilised |
Available Formats
- 5mg vial
- 10mg vial
Dissolution
Use our dilution calculator for precise concentration calculations.